Case–control study

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

Retrieved on: 
Thursday, March 31, 2022
Company, Genta (company), Mission statement, Isotretinoin, AFT, NYSE, CI, CMC, Conference, Standard of care, Food, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Industry, Securities Exchange Act of 1934, Securities Act of 1933, Ichthyosis, TSC, Journal of the European Academy of Dermatology and Venereology, Intellectual property, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Program, Chemistry, Case–control study, American Academy, Fas, Nature, Annual report, FDA, Security (finance), Pharmaceutical industry, Audit, Lumber, Dermatology

BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, Timber achieved multiple milestones over the past few months.
  • Its an exciting time at Timber as we move into late-stage clinical development for our two lead assets.
  • Timber ended the fourth quarter with $16.8 million in cash and common shares outstanding of 63.6 million on December 31, 2021.
  • Timber recognized revenue of $190,005 in the fourth quarter of 2021 compared to $102,382 for the fourth quarter of 2020.

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

Retrieved on: 
Wednesday, November 17, 2021
Investor relations, Security (finance), Securities Act of 1933, CMC, Genta (company), Industry, Annual report, Private Securities Litigation Reform Act, Company, NYSE, U.S. Securities and Exchange Commission, Nature, Intellectual property, Securities Exchange Act of 1934, GLOBE, Ichthyosis, TSC, Fas, Case–control study, Chemistry, Pharmaceutical industry

BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will host a conference call for investors and shareholders to discuss the positive topline results from its recently completed Phase 2b CONTROL Study of Congenital Ichthyosis for its lead asset, TMB-001. The call will be hosted by Timber’s Chief Executive Officer, John Koconis, and Chief Medical Officer, Alan Mendelsohn, M.D.

Key Points: 
  • The call will be hosted by Timbers Chief Executive Officer, John Koconis, and Chief Medical Officer, Alan Mendelsohn, M.D.
  • Dial in: (833) 685-0983 and ask to be joined into the Timber Pharmaceuticals call.
  • Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results

Retrieved on: 
Tuesday, August 10, 2021
CMC, Scleroderma, Industry, Ichthyosis, Nature, Patent, Company, Patient, Annual report, Chemistry, Â, U.S. Securities and Exchange Commission, CONTROL, TSC, Security (finance), Program, Securities Exchange Act of 1934, NYSE, AFT, No, Private Securities Litigation Reform Act, Case–control study, Fas, Securities Act of 1933, Intellectual property, FDA, Genta (company), GLOBE, Pharmaceutical industry

BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2021.
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, In the second quarter Timbers core programs for rare and orphan dermatologic diseases all continued to progress.
  • Timber expects to announce top line results from the Phase 2b CONTROL study in the fourth quarter of 2021 and is planning for an end-of-Phase 2 meeting with the FDA by the end of the year.
  • Timber ended the second quarter with $6.1 million in cash and common shares outstanding of 36.7 million at June 30, 2021.